PURPOSE: To evaluate childhood cancer survivors' adherence to surveillance protocols for late effects of treatment and to determine the factors affecting adherence. METHODS: Between 2014 and 2016, 11,337 survivors and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining adherence to Children's Oncology Group (COG) guidelines for survivors at high risk for second malignant neoplasms or cardiac dysfunction and to the American Cancer Society (ACS) cancer screening guidelines for average-risk populations. Adherence rates and factors affecting adherence were analyzed. RESULTS: Median age at diagnosis was 7 years (range, 0-20.9 years), and median time from diagnosis was 29 years (range, 15-47 years). Among high-risk survivors, adherence to COG breast, colorectal, skin, and cardiac surveillance was 12.6% (95% CI, 10.0% to 15.3%), 37.0% (34.1% to 39.9%), 22.3% (21.2% to 23.4%), and 41.4% (40.1% to 42.7%), respectively. Among average-risk survivors, adherence to ACS breast, cervical, and colorectal screening was 57.1% (53.2% to 61.0%), 83.6% (82.7% to 84.5%), and 68.5% (64.7% to 72.2%), respectively. Twenty-seven percent of survivors and 20.0% of primary care providers (PCPs) had a survivorship care plan (SCP). For high-risk survivors, SCP possession was associated with increased adherence to COG breast (22.3% v. 8.1%; prevalence ratio [PR], 2.52; CI, 1.59 to 4.01), skin (34.8% v 23.0%; PR, 1.16; CI, 1.01 to 1.33), and cardiac (67.0% v 33.1%; PR, 1.73; CI, 1.55 to 1.92) surveillance. For high-risk survivors, PCP possession of a SCP was associated only with increased adherence to COG skin cancer surveillance (36.9% v 23.2%; PR, 1.24; CI, 1.08 to 1.43). CONCLUSION: Guideline adherence is suboptimal. Although survivor SCP possession is associated with better adherence, few survivors and PCPs have one. New strategies to improve adherence are needed.
PURPOSE: To evaluate childhood cancer survivors' adherence to surveillance protocols for late effects of treatment and to determine the factors affecting adherence. METHODS: Between 2014 and 2016, 11,337 survivors and 2,146 siblings in the Childhood Cancer Survivor Study completed a survey ascertaining adherence to Children's Oncology Group (COG) guidelines for survivors at high risk for second malignant neoplasms or cardiac dysfunction and to the American Cancer Society (ACS) cancer screening guidelines for average-risk populations. Adherence rates and factors affecting adherence were analyzed. RESULTS: Median age at diagnosis was 7 years (range, 0-20.9 years), and median time from diagnosis was 29 years (range, 15-47 years). Among high-risk survivors, adherence to COG breast, colorectal, skin, and cardiac surveillance was 12.6% (95% CI, 10.0% to 15.3%), 37.0% (34.1% to 39.9%), 22.3% (21.2% to 23.4%), and 41.4% (40.1% to 42.7%), respectively. Among average-risk survivors, adherence to ACS breast, cervical, and colorectal screening was 57.1% (53.2% to 61.0%), 83.6% (82.7% to 84.5%), and 68.5% (64.7% to 72.2%), respectively. Twenty-seven percent of survivors and 20.0% of primary care providers (PCPs) had a survivorship care plan (SCP). For high-risk survivors, SCP possession was associated with increased adherence to COG breast (22.3% v. 8.1%; prevalence ratio [PR], 2.52; CI, 1.59 to 4.01), skin (34.8% v 23.0%; PR, 1.16; CI, 1.01 to 1.33), and cardiac (67.0% v 33.1%; PR, 1.73; CI, 1.55 to 1.92) surveillance. For high-risk survivors, PCP possession of a SCP was associated only with increased adherence to COG skin cancer surveillance (36.9% v 23.2%; PR, 1.24; CI, 1.08 to 1.43). CONCLUSION: Guideline adherence is suboptimal. Although survivor SCP possession is associated with better adherence, few survivors and PCPs have one. New strategies to improve adherence are needed.
Authors: Paul Craig Nathan; Kirsten Kimberlie Ness; Martin Christopher Mahoney; Zhenghong Li; Melissa Maria Hudson; Jennifer Sylene Ford; Wendy Landier; Marilyn Stovall; Gregory Thomas Armstrong; Tara Olive Henderson; Leslie L Robison; Kevin Charles Oeffinger Journal: Ann Intern Med Date: 2010-10-05 Impact factor: 25.391
Authors: Carmen L Wilson; Kayla Stratton; Wendy L Leisenring; Kevin C Oeffinger; Paul C Nathan; Karen Wasilewski-Masker; Melissa M Hudson; Sharon M Castellino; Marilyn Stovall; Gregory T Armstrong; Tara M Brinkman; Kevin R Krull; Leslie L Robison; Kirsten K Ness Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-05-19 Impact factor: 4.254
Authors: M Monica Gramatges; Francesca Bonaduce de Nigris; Jason King; Marc E Horowitz; Michael Fordis; David G Poplack Journal: Oncology (Williston Park) Date: 2018-01-15 Impact factor: 2.990
Authors: Eugene Suh; Christopher K Daugherty; Kristen Wroblewski; Hannah Lee; Mackenzie L Kigin; Kenneth A Rasinski; Jennifer S Ford; Emily S Tonorezos; Paul C Nathan; Kevin C Oeffinger; Tara O Henderson Journal: Ann Intern Med Date: 2014-01-07 Impact factor: 25.391
Authors: Daniel A Mulrooney; Gregory T Armstrong; Sujuan Huang; Kirsten K Ness; Matthew J Ehrhardt; Vijaya M Joshi; Juan Carlos Plana; Elsayed Z Soliman; Daniel M Green; Deokumar Srivastava; Aimee Santucci; Matthew J Krasin; Leslie L Robison; Melissa M Hudson Journal: Ann Intern Med Date: 2016-01-05 Impact factor: 25.391
Authors: Leslie L Robison; Ann C Mertens; John D Boice; Norman E Breslow; Sarah S Donaldson; Daniel M Green; Frederic P Li; Anna T Meadows; John J Mulvihill; Joseph P Neglia; Mark E Nesbit; Roger J Packer; John D Potter; Charles A Sklar; Malcolm A Smith; Marilyn Stovall; Louise C Strong; Yutaka Yasui; Lonnie K Zeltzer Journal: Med Pediatr Oncol Date: 2002-04
Authors: Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger Journal: JAMA Date: 2003-09-24 Impact factor: 157.335
Authors: Jennifer M Yeh; Kathryn P Lowry; Clyde B Schechter; Lisa R Diller; Oguzhan Alagoz; Gregory T Armstrong; John M Hampton; Wendy Leisenring; Qi Liu; Jeanne S Mandelblatt; Diana L Miglioretti; Chaya S Moskowitz; Kevin C Oeffinger; Amy Trentham-Dietz; Natasha K Stout Journal: Ann Intern Med Date: 2020-07-07 Impact factor: 25.391
Authors: Daniel Sierra-Lara Martinez; Peter A Noseworthy; Oguz Akbilgic; Joerg Herrmann; Kathryn J Ruddy; Abdulaziz Hamid; Ragasnehith Maddula; Ashima Singh; Robert Davis; Fatma Gunturkun; John L Jefferies; Sherry-Ann Brown Journal: Am Heart J Plus Date: 2022-04-01
Authors: Emily S Tonorezos; Richard J Cohn; Adam W Glaser; Jeremy Lewin; Eileen Poon; Claire E Wakefield; Kevin C Oeffinger Journal: Lancet Date: 2022-04-16 Impact factor: 202.731
Authors: Kevin T Lynch; William J Kane; Mark A Fleming; Raj P Desai; Shayna L Showalter; Craig L Slingluff; Daniel E Levin; Traci L Hedrick Journal: J Surg Oncol Date: 2021-03-31 Impact factor: 2.885
Authors: Sally Cohen-Cutler; Arthur Olch; Kenneth Wong; Jemily Malvar; Richard Sposto; Pierre Kobierski; Amit Sura; Louis S Constine; David R Freyer Journal: Cancer Med Date: 2020-12-16 Impact factor: 4.452
Authors: Courtney E Wimberly; Lisa Towry; Caroline Caudill; Emily E Johnston; Kyle M Walsh Journal: Pediatr Blood Cancer Date: 2021-02-09 Impact factor: 3.167
Authors: Matthew J Ehrhardt; Zachary J Ward; Qi Liu; Aeysha Chaudhry; Anju Nohria; William Border; Joy M Fulbright; Daniel A Mulrooney; Kevin C Oeffinger; Paul C Nathan; Wendy M Leisenring; Louis S Constine; Todd M Gibson; Eric J Chow; Rebecca M Howell; Leslie L Robison; Gregory T Armstrong; Melissa M Hudson; Lisa Diller; Yutaka Yasui; Saro H Armenian; Jennifer M Yeh Journal: J Clin Oncol Date: 2020-08-14 Impact factor: 50.717
Authors: Dalia Kagramanov; Rinku Sutradhar; Cindy Lau; Zhan Yao; Jason D Pole; Nancy N Baxter; Sumit Gupta; Paul C Nathan Journal: Cancer Med Date: 2021-06-15 Impact factor: 4.452